Morphological features of IFN-γ–stimulated mesenchymal stromal cells predict overall immunosuppressive capacity

Significance Substantial evidence exists demonstrating the immunosuppressive function of mesenchymal stromal cells (MSCs), but inconsistent clinical results suggest that better understanding of MSC-mediated immunosuppression and identification of features predictive of immunosuppressive capacity would advance MSC-based therapeutics. In this work, we present a robust analytical approach to quantify the immunosuppressive capacity of MSCs by integrating high-dimensional flow cytometry data from multiple experimental conditions into a single measure of immunosuppressive capacity. Additionally, we identified morphological features of MSCs that predicted immunosuppressive capacity, as well as the magnitude of IFN-γ–mediated immunosuppression enhancement. These improved methods of MSC characterization could be used to identify MSC preparations with desired immunosuppressive capacity, as well as screen for pretreatments that enhance their immunosuppressive function. Human mesenchymal stromal cell (MSC) lines can vary significantly in their functional characteristics, and the effectiveness of MSC-based therapeutics may be realized by finding predictive features associated with MSC function. To identify features associated with immunosuppressive capacity in MSCs, we developed a robust in vitro assay that uses principal-component analysis to integrate multidimensional flow cytometry data into a single measurement of MSC-mediated inhibition of T-cell activation. We used this assay to correlate single-cell morphological data with overall immunosuppressive capacity in a cohort of MSC lines derived from different donors and manufacturing conditions. MSC morphology after IFN-γ stimulation significantly correlated with immunosuppressive capacity and accurately predicted the immunosuppressive capacity of MSC lines in a validation cohort. IFN-γ enhanced the immunosuppressive capacity of all MSC lines, and morphology predicted the magnitude of IFN-γ–enhanced immunosuppressive activity. Together, these data identify MSC morphology as a predictive feature of MSC immunosuppressive function.

[1]  D J Prockop,et al.  Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Li,et al.  Negative regulation of interferon-γ/STAT1 signaling through cell adhesion and cell density-dependent STAT1 dephosphorylation. , 2011, Cellular signalling.

[3]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[4]  Jean Imbert,et al.  Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. , 2006, Cytokine & growth factor reviews.

[5]  D. Hursh,et al.  In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter. , 2016, Cytotherapy.

[6]  S. Bauer,et al.  Global proteomic signature of undifferentiated human bone marrow stromal cells: evidence for donor-to-donor proteome heterogeneity. , 2013, Stem cell research.

[7]  Sumona Sarkar,et al.  Machine learning based methodology to identify cell shape phenotypes associated with microenvironmental cues. , 2016, Biomaterials.

[8]  D. Prockop,et al.  Methods and protocols. Preface. , 2008, Methods in molecular biology.

[9]  John M Centanni,et al.  A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. , 2015, Cytotherapy.

[10]  D. Prockop,et al.  Mesenchymal Stem Cells. Methods and Protocols. , 2010, Anticancer research.

[11]  S. Setty,et al.  IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease , 2008, European journal of immunology.

[12]  Ross A. Marklein,et al.  Identification of Predictive Gene Markers for Multipotent Stromal Cell Proliferation. , 2016, Stem cells and development.

[13]  F. Lanza,et al.  A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. , 2011, Cytotherapy.

[14]  T. Ritter,et al.  Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots? , 2013, Stem cells.

[15]  Hiroyuki Honda,et al.  Morphology-Based Prediction of Osteogenic Differentiation Potential of Human Mesenchymal Stem Cells , 2013, PloS one.

[16]  D. Phinney Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy , 2012, Journal of cellular biochemistry.

[17]  Glyn Stacey,et al.  Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation , 2014 .

[18]  K. Tarte,et al.  Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. , 2013, Cytotherapy.

[19]  Matt J. Whitfield,et al.  Onset of heterogeneity in culture-expanded bone marrow stromal cells. , 2013, Stem cell research.

[20]  ViswanathanSowmya,et al.  Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. , 2014 .

[21]  K. English Mechanisms of mesenchymal stromal cell immunomodulation , 2013, Immunology and cell biology.

[22]  Bryan A. Millis,et al.  Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells. , 2013, Cytotherapy.

[23]  G. Nolan,et al.  High-Dimensional Single Cell Analysis , 2014, Current Topics in Microbiology and Immunology.

[24]  Jian-xin Lin,et al.  IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. , 2011, Current opinion in immunology.

[25]  J. Galipeau,et al.  IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells , 2014, The Journal of Immunology.

[26]  E. Ortega,et al.  Interferon gamma induces actin polymerization, Rac1 activation and down regulates phagocytosis in human monocytic cells. , 2012, Cytokine.

[27]  M. Krampera,et al.  Mesenchymal stem cells and autoimmune diseases. , 2011, Best practice & research. Clinical haematology.

[28]  Joachim Kohn,et al.  Cytoskeleton-based forecasting of stem cell lineage fates , 2009, Proceedings of the National Academy of Sciences.

[29]  R. Puri,et al.  MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.

[30]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[31]  Anne E Carpenter,et al.  CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.

[32]  S. Bauer,et al.  Chromosomal stability of mesenchymal stromal cells during in vitro culture. , 2016, Cytotherapy.

[33]  Wong Cheng Lee,et al.  Multivariate biophysical markers predictive of mesenchymal stromal cell multipotency , 2014, Proceedings of the National Academy of Sciences.

[34]  I. Sekiya,et al.  Expansion of Human Adult Stem Cells from Bone Marrow Stroma: Conditions that Maximize the Yields of Early Progenitors and Evaluate Their Quality , 2002, Stem cells.

[35]  D. Phinney Biochemical Heterogeneity of Mesenchymal Stem Cell Populations: Clues to their Therapeutic Efficacy , 2007, Cell cycle.

[36]  K. Keyvanfar,et al.  Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. , 2015, Cytotherapy.

[37]  Jacques Galipeau,et al.  The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. , 2015, Cytotherapy.

[38]  Todd C McDevitt,et al.  Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion. , 2014, Cytotherapy.

[39]  A. Reinisch,et al.  A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance , 2015, Stem Cell Research & Therapy.

[40]  Nathan O. Loewke,et al.  Dynamic and social behaviors of human pluripotent stem cells , 2015, Scientific Reports.

[41]  D. Discher,et al.  Mechanobiology of bone marrow stem cells: from myosin-II forces to compliance of matrix and nucleus in cell forms and fates. , 2013, Differentiation; research in biological diversity.

[42]  Dennis E. Discher,et al.  Physical plasticity of the nucleus in stem cell differentiation , 2007, Proceedings of the National Academy of Sciences.

[43]  J. Galipeau,et al.  Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[44]  Luis A Solchaga,et al.  Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. , 2012, American journal of stem cells.

[45]  A. Ho,et al.  Heterogeneity of mesenchymal stromal cell preparations. , 2008, Cytotherapy.

[46]  I. Sekiya,et al.  Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. , 2001, Cytotherapy.

[47]  A. Ventura,et al.  The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation. , 2010, Cytotherapy.

[48]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[49]  Ivan Martin,et al.  International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. , 2016, Cytotherapy.

[50]  R. Tuan,et al.  Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells , 2014, Stem cells.

[51]  M. Klinker,et al.  Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models. , 2015, World journal of stem cells.

[52]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[53]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[54]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[55]  Sean X. Sun,et al.  Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single‐cell resolution , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  Allison Hubel,et al.  Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices , 2014, Transfusion.

[57]  Abhishek Kumar,et al.  Correlated spatio-temporal fluctuations in chromatin compaction states characterize stem cells. , 2013, Biophysical journal.

[58]  K. V. Van Vliet,et al.  Concise Review: When Colonies Are Not Clones: Evidence and Implications of Intracolony Heterogeneity in Mesenchymal Stem Cells , 2016, Stem cells.

[59]  Ross A. Marklein,et al.  High Content Imaging of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human Mesenchymal Stem Cells upon Osteogenic Induction , 2016, Stem cells.

[60]  J. L. Surdo,et al.  Toward Improved Characterization of Human Mesenchymal Stem Cells for Use in Cellular Therapies: A Regulatory Science Perspective , 2013 .

[61]  R. Puri,et al.  Gene markers of cellular aging in human multipotent stromal cells in culture , 2014, Stem Cell Research & Therapy.

[62]  H. Kelchtermans,et al.  Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis , 2010, Arthritis research & therapy.